Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 17/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.61 |
| ▸ | RAF1 | P04049 | 14/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 3/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 5/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414626 | 0.90 | CYP1A2 (0.61) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5420450 | 0.84 | BRAF (0.68) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5420446 | 0.84 | BRAF (0.68) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5126749 | 0.82 | BRAF (0.48) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5410796 | 0.81 | BRAF (0.77) | RAF1BRAFALOX5 | |
| SCHEMBL5406008 | 0.81 | CYP1A2 (0.44) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5402908 | 0.80 | BRAF (0.71) | RAF1BRAFALOX5 | |
| SCHEMBL5419052 | 0.80 | BRAF (0.50) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6229238 | 0.79 | BRAF (0.47) | MAPK14RAF1BRAF | |
| SCHEMBL5414747 | 0.77 | BRAF (0.54) | RAF1BRAFALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | claimed |
| EP-1318992-B1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-07-27 | — | — | EP | claimed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1318992-B1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| CN-1471523-A | Imidazole derivatives as Raf kinase inhibitors | ʷ | 2004-01-28 | — | — | CN | disclosed |
| EP-1318992-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024680-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | MAPK13 623/4885MAPK12 529/4885MAPK11 568/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK13 80/4885MAPK12 108/4885MAPK11 111/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK13 68/4885MAPK12 98/4885MAPK11 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.